Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00993850 · ClinicalTrials.gov registry record · Phase 3
Sleep Disturbance and Bipolar Disorder
A Phase 3 study of Bipolar Disorder and Dyssomnias, sponsored by University of California, Berkeley.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00993850: Completed Phase 3 study of Bipolar Disorder and Dyssomnias, sponsored by University of California, Berkeley.
NCT00993850 is a Phase 3 study of Bipolar Disorder and Dyssomnias that has completed, run by University of California, Berkeley. The registered enrollment target is 52 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00993850, a Phase 3 study of Bipolar Disorder and Dyssomnias, has completed, sponsored by University of California, Berkeley.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to evaluate a psychological intervention for individuals who suffer from sleep disturbance and bipolar disorder. We are hoping that this treatment will: (1) improve the quality of life of individuals with bipolar disorder who are suffering from sleep disturbance and (2) reduce the risk of, or help prevent, episodes.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive behavioral therapy for insomnia
- OTHER Bipolar education
Study Locations (1)
California
- University of California at Berkeley - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
What the finished NCT00993850 record still lists
NCT00993850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Cognitive behavioral therapy for insomnia is the first listed.
NCT00993850 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00993850 about?
NCT00993850 is a clinical study titled "Sleep Disturbance and Bipolar Disorder". The study aims to evaluate a psychological intervention for individuals who suffer from sleep disturbance and bipolar disorder. We are hoping that this treatment will: (1) improve the quality of life of individuals with bipolar disorder who are suffering from sleep disturbance and (2) reduce the ris...
What is the current status of trial NCT00993850?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2009-10. Estimated completion is 2012-07.
What conditions does trial NCT00993850 study?
This clinical trial studies the following conditions: Bipolar Disorder, Dyssomnias.
What interventions are being tested in trial NCT00993850?
The interventions under investigation include: Cognitive behavioral therapy for insomnia (BEHAVIORAL), Bipolar education (OTHER).
Who is sponsoring clinical trial NCT00993850?
This trial is sponsored by University of California, Berkeley, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00993850 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00993850's enrollment target sits among peer trials
52 105th of 162 higher than 56 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RECRUITING · Phase 3
-
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RECRUITING · Phase 3
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RECRUITING · Phase 3
-
Study of Aripiprazole (Abilify) in Children With Symptoms of Mania
COMPLETED · Phase 3
-
Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression
COMPLETED · Phase 3
-
Acute Treatment of Bipolar II Depression
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia